HLA-DMB Antibody

What is HLA-DMB and what is its role in the immune system?

HLA-DMB (major histocompatibility complex, class II, DM beta) is a protein that forms a heterodimer with HLA-DMA (alpha chain), both anchored in the membrane of intracellular vesicles . This complex plays a critical role in the peptide loading of MHC class II molecules by catalyzing the release of the class II-associated invariant chain peptide (CLIP) from newly synthesized MHC class II molecules, thereby freeing the peptide binding site for acquisition of antigenic peptides .

The HLA-DMB gene is mapped to chromosome 6p21.32 and belongs to the HLA class II beta chain paralogues . The beta chain is approximately 26-28 kDa and its gene contains 6 exons . HLA-DMA and -DMB encode subunits of a functional heterodimer that is critical in the pathway of class II antigen presentation to CD4+ T cells .

What cell types express HLA-DMB?

HLA-DMB is primarily expressed in antigen presenting cells (APCs), including:

• B lymphocytes

• Dendritic cells

• Macrophages

Expression can be induced or enhanced by interferon-γ (IFN-γ) treatment in various cell types, including endothelial cells, which is an important consideration for experimental design .

What are the validated applications for HLA-DMB antibodies in research?

Based on current research, HLA-DMB antibodies have been validated for multiple applications with specific dilution recommendations:

Note: Sample-dependent optimization is recommended for all applications

How should researchers validate HLA-DMB antibody specificity?

Proper validation of HLA-DMB antibodies involves a multi-step approach:

• Positive control testing: Use established positive controls such as JURKAT, RAJI, or HUT whole cell lysates for Western blot and human mammary cancer tissue for IHC applications .

• Blocking experiments: Utilize recombinant protein control fragments (e.g., Human HLA-DMB aa 18-118 fragment) . Pre-incubate the antibody with 100x molar excess of protein fragment control for 30 minutes at room temperature before application .

• Knockdown validation: For definitive specificity confirmation, perform lentiviral knockdown of HLA-DMB in relevant cell types and confirm loss of antibody signal .

• Cross-reactivity assessment: Consider sequence homology with orthologs (mouse and rat orthologs show approximately 70% sequence identity) .

How are HLA-DMB polymorphisms associated with disease susceptibility?

HLA-DMB polymorphisms have been implicated in several diseases:

• HIV-related Kaposi's sarcoma: SNP screening identified HLA-DMB rs6902982 as a candidate susceptibility gene, passing the significance threshold of 5% after Bonferroni correction .

• Type 1 Diabetes Mellitus: HLA-DMB has been associated with susceptibility to this autoimmune condition .

• Psychologic Dyspareunia: Listed as a disease association in genomic databases .

The mechanisms underlying these associations likely involve altered antigen presentation affecting T cell responses to specific pathogens or self-antigens.

What is the role of HLA-DMB in transplant rejection mechanisms?

HLA-DMB, as part of the HLA class II system, plays a significant role in transplant immunity:

• Antibody-mediated rejection: HLA class II antibodies, including those potentially targeting HLA-DM complexes, can induce necrotic cell death in endothelial cells through a pathway independent of apoptosis and necroptosis .

• Lysosomal pathway activation: The mechanism involves lysosomal membrane permeabilization (LMP) and reorganization of the actin cytoskeleton .

• Mitochondrial stress: HLA-DR-dependent actin stress fiber formation and LMP lead to decreased mitochondrial membrane potential and generation of reactive oxygen species in endothelial cells .

Understanding these mechanisms is crucial for developing therapeutic approaches to prevent antibody-mediated rejection in solid organ transplantation.

How do HLA class II genes including HLA-DMB influence vaccine efficacy?

Research on the Japanese encephalitis vaccine has demonstrated that HLA class II genes significantly influence antibody responses:

• Allele-specific responses: Different HLA-DQB1 alleles showed opposing effects on neutralizing antibody seroconversion. For example, HLA-DQB102:01 was associated with better response, while HLA-DQB102:02 was associated with poorer response .

• Amino acid variations: Single amino acid differences in HLA class II molecules can dramatically alter peptide binding and subsequent antibody responses. For instance, DQB1 residue S57 versus V57 showed opposite effects on Japanese encephalitis virus-neutralizing antibody responses .

• Peptide presentation differences: Computational analyses suggest that allelic differences can change which pathogen-derived peptides bind to MHC class II molecules, influencing T cell responses and subsequent antibody production .

This research emphasizes the importance of considering HLA genotypes in vaccine development and efficacy studies.

How does HLA-DMB interact with other components of the MHC class II pathway?

The HLA-DMB protein functions in a complex network:

• HLA-DMA interaction: Forms a functional heterodimer with HLA-DMA, with both chains anchored in the membrane of intracellular vesicles .

• CLIP displacement: The DM complex catalyzes the release of CLIP from newly synthesized MHC class II molecules, enabling binding of antigenic peptides .

• HLA-DO regulation: In B cells, the interaction between HLA-DM and MHC class II molecules is regulated by another protein, HLA-DO .

• Peptide editing function: Beyond CLIP removal, DM plays a role in "editing" the peptide repertoire, favoring the display of high-affinity peptides on MHC class II molecules .

What experimental approaches can determine the impact of HLA-DMB on immune checkpoint inhibitor efficacy?

Recent research has indicated HLA genotypes influence immune checkpoint inhibitor outcomes:

• HLA evolutionary divergence (HED): Studies have shown that high HED of the HLA-B locus correlates with better clinical outcomes in nivolumab (anti-PD-1 antibody) treatment of renal cell carcinoma, with improved cancer-specific survival compared to patients with low HED .

• CD8+ T cell infiltration: HLA-B diversity correlates with the number of infiltrated CD8+ cells in the tumor microenvironment (correlation coefficient 0.4042) .

• HLA-II zygosity effects: The presence of at least one homozygosity in HLA-II alleles significantly improved objective response to nivolumab (hazard ratio 0.34, 95% CI 0.21-0.96, p=0.042) .

While these studies focus primarily on HLA-A, B, C, DQB1, and DRB1, the functional role of HLA-DMB in peptide loading suggests it may also influence checkpoint inhibitor efficacy through effects on antigen presentation.

What are common challenges when using HLA-DMB antibodies and how can they be addressed?

Researchers frequently encounter several challenges when working with HLA-DMB antibodies:

• Intracellular localization: Since HLA-DMB is located in intracellular vesicles, proper permeabilization is essential for immunostaining applications. Consider using:

  • 0.1-0.5% Triton X-100 for cell permeabilization in IF/ICC applications

  • Optimized antigen retrieval for IHC (TE buffer pH 9.0 or citrate buffer pH 6.0)

• Expression level variations: HLA-DMB expression is influenced by cellular activation state and cytokine environment:

  • Pre-treat cells with IFN-γ to upregulate HLA class II expression for more robust detection

  • Use positive control cell lines (JURKAT, RAJI, HUT) known to express HLA-DMB

• Antibody specificity: Confirm specificity through:

  • Blocking experiments with recombinant HLA-DMB protein

  • Testing in multiple applications with appropriate controls

  • Reconstitution with 0.2 mL of distilled water to yield a concentration of 500 μg/mL for optimal results

What approaches can resolve data inconsistencies in HLA-DMB research?

When faced with conflicting or unexpected results:

• Genetic variation considerations: Allelic variations in HLA-DMB may affect antibody binding. Consider:

  • Using antibodies targeting conserved regions when working across diverse populations

  • Genotyping study populations to account for HLA-DMB polymorphisms that might affect results

• Cross-reactivity assessment: Check for potential cross-reactivity with:

  • Other HLA class II beta chains

  • The orthologs in mouse and rat (70% sequence identity)

• Experimental system optimization:

  • Adjust antibody concentrations based on expression levels in your specific system

  • Validate with multiple detection methods (e.g., complement both IF and Western blot)

  • Consider using recombinant protein control fragments in blocking experiments to confirm specificity

How might new technologies enhance HLA-DMB research?

Emerging technologies offer promising avenues for advanced HLA-DMB research:

• Single-cell analysis: Single-cell RNA sequencing and proteomics can reveal cell-specific expression patterns and functional variations of HLA-DMB in heterogeneous cell populations like tumor microenvironments or immune infiltrates.

• CRISPR-Cas9 gene editing: Precise modification of HLA-DMB can help determine:

  • The functional consequences of disease-associated polymorphisms

  • Structure-function relationships through targeted mutation of key residues

• Immunopeptidomics: High-performance liquid chromatography coupled to tandem mass spectrometry for HLA-bound peptide analysis can reveal how HLA-DMB variants influence the peptide repertoire presented by MHC class II molecules .

What are unresolved questions regarding HLA-DMB's role in precision medicine?

Several critical questions remain for translational research:

• Predictive biomarkers: Can HLA-DMB genotyping or functional assessment predict:

  • Response to immunotherapies beyond the currently studied immune checkpoint inhibitors

  • Vaccine efficacy in diverse populations

  • Risk of antibody-mediated rejection in transplantation

• Therapeutic targeting: Could modulation of HLA-DMB function:

  • Enhance vaccine responses in poor responders

  • Reduce rejection risk in organ transplantation

  • Augment cancer immunotherapy efficacy

• Integrated pathway effects: How do polymorphisms across the entire antigen processing and presentation pathway, including HLA-DMB, collectively influence immune responses? This systems biology approach may reveal emergent properties not evident when studying individual components.